Yahoo · Feb 26, 2026
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading
European equities traded in the US as American depositary receipts were sharply lower late Thursday
CL
NASDAQ · CLLS
Cellectis S.A.
Healthcare · Biotechnology
$1.61
Down-$0.19 (-11.80%)
Updated Sep 16, 2026, 2:52 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 523.7M
- P/E ratio
- -8.66
- Dividend yield
- 0.00%
- 52-week range
- $1.75 – $4.55
- Volume
- 781.23K
- Avg. volume
- 146.61K
Price performance
CLLS price history
1M range · 20 trading sessions · Daily adjusted prices
CLLS closed at $1.61 after 20 trading sessions, down 47.04% for the selected period.
- Last close
- $1.61
- Period change
- -47.04%
- Period low
- $1.61
- Period high
- $3.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.65 | $1.6877 | $1.55 | $1.61 | 781.23K |
| Sep 14, 2026 | $2.32 | $2.42 | $1.75 | $1.83 | 1.18M |
| Sep 11, 2026 | $3.105 | $3.18 | $3.01 | $3.10 | 75.58K |
| Sep 10, 2026 | $3.09 | $3.26 | $3.07 | $3.12 | 41.9K |
| Sep 9, 2026 | $3.07 | $3.19 | $3.01 | $3.13 | 9.49K |
| Sep 8, 2026 | $3.22 | $3.23 | $3.1245 | $3.16 | 37.47K |
| Sep 4, 2026 | $3.41 | $3.41 | $3.21 | $3.24 | 4.83K |
| Sep 3, 2026 | $3.39 | $3.445 | $3.26 | $3.32 | 20.93K |
| Sep 2, 2026 | $3.32 | $3.34 | $3.2199 | $3.25 | 7.3K |
| Sep 1, 2026 | $3.29 | $3.4973 | $3.1001 | $3.30 | 9.82K |
| Aug 31, 2026 | $3.34 | $3.52 | $3.30 | $3.35 | 13.19K |
| Aug 28, 2026 | $3.48 | $3.57 | $3.40 | $3.40 | 5.72K |
| Aug 27, 2026 | $3.55 | $3.60 | $3.4901 | $3.555 | 10.17K |
| Aug 26, 2026 | $3.44 | $3.50 | $3.38 | $3.42 | 17.95K |
| Aug 25, 2026 | $3.33 | $3.4705 | $3.305 | $3.42 | 15.89K |
| Aug 24, 2026 | $3.33 | $3.33 | $3.1267 | $3.19 | 17.33K |
| Aug 21, 2026 | $3.325 | $3.48 | $3.2009 | $3.405 | 26.66K |
| Aug 20, 2026 | $3.23 | $3.48 | $3.23 | $3.47 | 35.25K |
| Aug 19, 2026 | $3.12 | $3.17 | $3.109 | $3.17 | 5.95K |
| Aug 18, 2026 | $3.02 | $3.11 | $2.99 | $3.04 | 24.18K |
Latest CLLS news
The latest Smart Investors Daily articles mentioning CLLS.
Stock researchCompany · Overview
CLLS research
Overview
Company profile and research snapshot.
Company profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 7, 2026 | ODDO BHF | Buy | — |
| Jun 15, 2026 | JEFFERIES | Buy | — |
| May 12, 2026 | CITIZENS | Outperform | — |
| Feb 25, 2026 | JEFFERIES | Buy | — |
| Feb 9, 2026 | CITIZENS | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 17, 2026
European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were marginally lower late Tuesda
Yahoo · Feb 10, 2026
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
European equities traded in the US as American depositary receipts were little changed late Tuesday
Yahoo · Feb 9, 2026
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week modestly higher
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
